Get started
Author

KU Wittrup-Jensen

Observed names: K WITTRUP‐JENSEN, K Wittrup-Jensen, K. Wittrup-Jensen, K.U. Wittrup-Jensen
OpenAlex ID: A5037778922
Cost-Effectiveness Of Intravitreal Aflibercept Injection (IAI) In Treating Neovascular Age-Related Macular Degeneration In The US
2013 · R. Vitti, K.M. Clements, et al. · Value in Health · 4
Intravitrael Aflibercept Injection for The Treatment of Visual Impairment Due to Macular Oedema Secondary to Branch Retinal Vein Occlusion: Cost-Effectiveness Versus Ranibizumab
2015 · E Lovato, A Lloyd, et al. · Value in Health · 1
Cost-Minimization Analysis of Intravitreal Aflibercept (IVT-AFL) for Neovascular Age-Related Macular Degeneration in Spain
2013 · A. Garcia-Layana, A. Ortega, et al. · Value in Health · 1
The Cost-Effectiveness of Intravitreal Aflibercept (IVT-AFL) in Treating Neovascular Age-Related Macular Degeneration in an Italian Setting
2013 · A. D’Ausilio, E. Midena, et al. · Value in Health · 1
Costs of Prevalence-Based Central Retinal Vein Occlusion (CRVO) in the United Kingdom
2013 · J. Priaulx, K.U. Wittrup-Jensen · Value in Health · 1
Cost-Effectiveness of Intravitreal Aflibercept in Treating Neovascular Age-Related Macular Degeneration in Sweden
2013 · K.M. Clements, E.M. Hulbert, et al. · Value in Health · 1
Budgetary Impact Of Intravitreal Aflibercept Injection (IAI) In Treating Neovascular Age-Related Macular Degeneration In A US Health Plan Of Adults Ages 65 Years And Older
2013 · R. Vitti, K.M. Clements, et al. · Value in Health · 1
Pmh31 Predictors for Rehospitalization in Patients With Schizophrenia
2006 · H Gothe, A Höer, et al. · Value in Health · 1
Pdb21 Cost-effectiveness Analysis of Basal/bolus Therapy in Type-1 Diabetes Using Insulin Detemir + Insulin Aspart or Human Soluble Insulin-based Basal/bolus Regimens in Germany
2005 · WJ Valentine, KU Wittrup-Jensen, et al. · Value in Health · 1
Real-World Evaluation Of Physician Attitudes Towards The Prescription Of Androgen Deprivation Therapy For Patients With Prostate Cancer
2017 · KU Wittrup-Jensen, P Hallworth, et al. · Value in Health
Vision‐related function in the COPERNICUS and GALILEO trials
2014 · I PEARCE, K LORENZ, et al. · Acta Ophthalmologica
Pcv31 Us Budget Impact of Increasing Aspirin Usage for Primary and Secondary Prevention of Cardiovascular Disease
2009 · A Benedict, SC Manson, et al. · Value in Health
Puk9 Cost of Overactive Bladder in the United States
2008 · ML Ganz, AM Smalarz, et al. · Value in Health
PDF
Pdb28 Cost-effectiveness Analysis of Acarbose in the Prevention Oftype 2 Diabetes in South Korea
2007 · K JongMann, JP Clegg, et al. · Value in Health
PDF
Pdb56 an Assessment of the Long-term Outcome for Liraglutide+metformin Versus Metformin and Versus Metformin+glimepiride Intype-2 Patients With Inade-quate Glycaemic Control
2005 · M Hammer, WJ Valentine, et al. · Value in Health
Pdb23 Economic Evaluation of Detemir-based Basal/bolus Therapy Versus Nph-based Basal/bolus Therapy for Type-1 Diabetes in Germany
2005 · AJ Palmer, WJ Valentine, et al. · Value in Health
PDF
Pdb39 Evaluation of the Cost-utility of Insulin Detemir Compared to Insulin Glargine, Both in Combination With Insulin Aspart Intype-i Diabetes in Germany and Austria
2005 · S Roze, KU Wittrup-Jensen, et al. · Value in Health
PDF
Pdb24 Assessment of the Long-term Cost-effectiveness of Insulin Aspart + Metformin Versus Human Insulin + Metformin Regimens in Type-2 Diabetes in Germany Based on the Clinical Findings of the Phazit Study
2005 · S Roze, KU Wittrup-Jensen, et al. · Value in Health
PDF
Pdb19 Economic Evaluation of Switching Type-1 Diabetes Patients From Long-acting Insulin Glargine Ina Basal/bolus Regimen to Long-acting Insulin Detemir in an Austrian Setting
2005 · AJ Palmer, KU Wittrup-Jensen, et al. · Value in Health
Pdb28 Cost-effectiveness Analyses of Basal-bolus Therapy of Type-1 Diabetes Using Insulin Detemir + Human Soluble Insulin Versus Neutral Protamine Hagedorm + Human Soluble Insulin Regimens in Germany
2005 · WJ Valentine, AJ Palmer, et al. · Value in Health
Pdb14 Economic Evaluation of Detemir-based Basal/bolus Therapy Versus Neutral Protamine Hagedorn-based Basal/bolus Therapy for Type-1 Diabetes in a Dutch Setting
2005 · S Roze, K Wittrup-Jensen, et al. · Value in Health
Db6 Comparison of the Cost-effectiveness for Basal-bolus Therapy of Type-1 Diabetes Using Insulin Detemir+ Insulin Aspart or Human Insulin-based Regimens in the Netherlands
2005 · Valentine Wj, K Wittrup-Jensen, et al. · Value in Health
PDF
Pmdm4: Measurements of Health Status in Denmark
2000 · KU Wittrup-Jensen, R Brooks, et al. · Value in Health
PDF
Works count: 23
Citation count: 12
H-index: 1
I10-index:
Year
Topic
Type